

Michele Senni

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/240386/publications.pdf>

Version: 2024-02-01

171
papers

21,309
citations

34076

52
h-index

10724

138
g-index

184
all docs

184
docs citations

184
times ranked

14819
citing authors

#	ARTICLE	IF	CITATIONS
1	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. <i>European Heart Journal</i> , 2021, 42, 3599-3726.	1.0	5,558
2	Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. <i>New England Journal of Medicine</i> , 2020, 383, 1413-1424.	13.9	2,821
3	Angiotensinâ€“Nepriylsin Inhibition in Heart Failure with Preserved Ejection Fraction. <i>New England Journal of Medicine</i> , 2019, 381, 1609-1620.	13.9	1,485
4	Congestive Heart Failure in the Community. <i>Circulation</i> , 1998, 98, 2282-2289.	1.6	925
5	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. <i>European Journal of Heart Failure</i> , 2022, 24, 4-131.	2.9	820
6	The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. <i>European Heart Journal</i> , 2012, 33, 1750-1757.	1.0	652
7	Angiotensin Receptor Nepriylsin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure. <i>Circulation</i> , 2015, 131, 54-61.	1.6	552
8	Congestive Heart Failure in the Community. <i>Archives of Internal Medicine</i> , 1999, 159, 29.	4.3	335
9	New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes. <i>European Heart Journal</i> , 2014, 35, 2797-2815.	1.0	304
10	Renal Effects and Associated Outcomes During Angiotensin-Nepriylsin Inhibition in Heart Failure. <i>JACC: Heart Failure</i> , 2018, 6, 489-498.	1.9	272
11	Developing Therapies for Heart Failure Withâ€“Preservedâ€“Ejection Fraction. <i>JACC: Heart Failure</i> , 2014, 2, 97-112.	1.9	267
12	Impact of Diabetes on Epidemiology, Treatment, and Outcomes of Patients Withâ€“Heart Failure. <i>JACC: Heart Failure</i> , 2015, 3, 136-145.	1.9	265
13	Clinical Presentation and Outcome in a Contemporary Cohort of Patients With Acute Myocarditis. <i>Circulation</i> , 2018, 138, 1088-1099.	1.6	253
14	Heart failure with preserved systolic function. <i>Journal of the American College of Cardiology</i> , 2001, 38, 1277-1282.	1.2	247
15	Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study. <i>European Journal of Heart Failure</i> , 2019, 21, 998-1007.	2.9	233
16	Influence of Mitral Regurgitation Repair on Survival in the Surgical Treatment for Ischemic Heart Failure Trial. <i>Circulation</i> , 2012, 125, 2639-2648.	1.6	210
17	Baroreflex Activation Therapy for the Treatment of Heart Failure With a Reducedâ€“Ejection Fraction. <i>JACC: Heart Failure</i> , 2015, 3, 487-496.	1.9	204
18	Mode of Death in Heart Failure With Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2017, 69, 556-569.	1.2	193

#	ARTICLE	IF	CITATIONS
19	Prediction of right ventricular failure after ventricular assist device implant: systematic review and meta-analysis of observational studies. <i>European Journal of Heart Failure</i> , 2017, 19, 926-946.	2.9	188
20	Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimens. <i>European Journal of Heart Failure</i> , 2016, 18, 1193-1202.	2.9	180
21	Thirty Years of Evidence on the Efficacy of Drug Treatments for Chronic Heart Failure With Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2017, 10, .	1.6	178
22	Multicenter Prospective Observational Study on Acute and Chronic Heart Failure. <i>Circulation: Heart Failure</i> , 2013, 6, 473-481.	1.6	170
23	Temporal Relation Between Myocardial Fibrosis and Heart Failure With Preserved Ejection Fraction. <i>JAMA Cardiology</i> , 2017, 2, 995.	3.0	164
24	Clinical features and outcomes of elderly outpatients with heart failure followed up in hospital cardiology units: Data from a large nationwide cardiology database (IN-CHF Registry). <i>American Heart Journal</i> , 2002, 143, 45-55.	1.2	162
25	Transaortic Chordal Cutting. <i>Journal of the American College of Cardiology</i> , 2015, 66, 1687-1696.	1.2	141
26	Use of echocardiography in the management of congestive heart failure in the community. <i>Journal of the American College of Cardiology</i> , 1999, 33, 164-170.	1.2	140
27	Diastolic heart failure in the community: Clinical profile, natural history, therapy, and impact of proposed diagnostic criteria. <i>Journal of Cardiac Failure</i> , 2002, 8, 279-287.	0.7	134
28	Prevalence and prognostic impact of noncardiac comorbidities in heart failure outpatients with preserved and reduced ejection fraction: a community-based study. <i>European Journal of Heart Failure</i> , 2018, 20, 1257-1266.	2.9	130
29	Comparing LCZ696 With Enalapril According to Baseline Risk Using the MAGGIC and EMPHASIS-HF Risk Scores. <i>Journal of the American College of Cardiology</i> , 2015, 66, 2059-2071.	1.2	118
30	Prevalence, Characteristics, and Outcomes of COVID-19-Associated Acute Myocarditis. <i>Circulation</i> , 2022, 145, 1123-1139.	1.6	118
31	Neprilysin inhibition in heart failure: mechanisms and substrates beyond modulating natriuretic peptides. <i>European Journal of Heart Failure</i> , 2017, 19, 710-717.	2.9	116
32	Geographic variations in the PARADIGM-HF heart failure trial. <i>European Heart Journal</i> , 2016, 37, 3167-3174.	1.0	114
33	Acute heart failure patient profiles, management and in-hospital outcome: results of the Italian Registry on Heart Failure Outcome. <i>European Journal of Heart Failure</i> , 2012, 14, 1208-1217.	2.9	112
34	Predicting heart failure outcome from cardiac and comorbid conditions: The 3C-HF score. <i>International Journal of Cardiology</i> , 2013, 163, 206-211.	0.8	108
35	Relationship of serum sodium concentration to mortality in a wide spectrum of heart failure patients with preserved and with reduced ejection fraction: an individual patient data meta-analysis. <i>European Journal of Heart Failure</i> , 2012, 14, 1139-1146.	2.9	100
36	In-hospital and 1-year outcomes of acute heart failure patients according to presentation (de novo vs.) <i>Tj ETQq0 0 0 rgBT /Overlock 10 T Cardiology</i> , 2014, 173, 163-169.	0.8	98

#	ARTICLE	IF	CITATIONS
37	Incremental Value of Gait Speed in Predicting Prognosis of Older Adults With Heart Failure. <i>JACC: Heart Failure</i> , 2016, 4, 289-298.	1.9	93
38	Left ventricular systolic and diastolic function after pericardiectomy in patients with constrictive pericarditis. <i>Journal of the American College of Cardiology</i> , 1999, 33, 1182-1188.	1.2	89
39	A contemporary European experience with surgical septal myectomy in hypertrophic cardiomyopathy. <i>European Heart Journal</i> , 2012, 33, 2080-2087.	1.0	88
40	Role of biomarkers in cardiac structure phenotyping in heart failure with preserved ejection fraction: critical appraisal and practical use. <i>European Journal of Heart Failure</i> , 2015, 17, 1231-1239.	2.9	85
41	Baroreflex activation therapy for the treatment of heart failure with a reduced ejection fraction: safety and efficacy in patients with and without cardiac resynchronization therapy. <i>European Journal of Heart Failure</i> , 2015, 17, 1066-1074.	2.9	85
42	Angiotensin-Nepriylsin Inhibition and Renal Outcomes in Heart Failure With Preserved Ejection Fraction. <i>Circulation</i> , 2020, 142, 1236-1245.	1.6	81
43	A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure. <i>European Heart Journal</i> , 2015, 36, 434-439.	1.0	80
44	Association between renal function and cardiovascular structure and function in heart failure with preserved ejection fraction. <i>European Heart Journal</i> , 2014, 35, 3442-3451.	1.0	78
45	Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction. <i>European Heart Journal</i> , 2021, 42, 3741-3752.	1.0	74
46	Spectrum of epidemiological and clinical findings in patients with heart failure with preserved ejection fraction stratified by study design: a systematic review. <i>European Journal of Heart Failure</i> , 2016, 18, 54-65.	2.9	73
47	Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 1919.	3.8	72
48	Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 302	2.9	65
49	Fibrinogen is an Independent Marker for Thoracic Aortic Atherosclerosis. <i>American Journal of Cardiology</i> , 1998, 81, 321-326.	0.7	64
50	End-systolic pressure/volume relationship during dobutamine stress echo: a prognostically useful non-invasive index of left ventricular contractility. <i>European Heart Journal</i> , 2005, 26, 2404-2412.	1.0	64
51	Noncardiac Versus Cardiac Mortality in Heart Failure With Preserved, Midrange, and Reduced Ejection Fraction. <i>Journal of the American Heart Association</i> , 2019, 8, e013441.	1.6	62
52	Impact of systolic blood pressure on the safety and tolerability of initiating and up-titrating sacubitril/valsartan in patients with heart failure and reduced ejection fraction: insights from the TITRATION study. <i>European Journal of Heart Failure</i> , 2018, 20, 491-500.	2.9	59
53	Relation of Serum Uric Acid Levels and Outcomes Among Patients Hospitalized for Worsening Heart Failure With Reduced Ejection Fraction (from the Efficacy of Vasopressin Antagonism in Heart Failure) Tj ETQq1 1 0 784314 rgBT /Overlock	1.0	58
54	Differing prognostic value of pulse pressure in patients with heart failure with reduced or preserved ejection fraction: results from the MAGGIC individual patient meta-analysis. <i>European Heart Journal</i> , 2015, 36, 1106-1114.	1.0	53

#	ARTICLE	IF	CITATIONS
55	A Novel Prognostic Index to Determine the Impact of Cardiac Conditions and Co-Morbidities on One-Year Outcome in Patients With Heart Failure. <i>American Journal of Cardiology</i> , 2006, 98, 1076-1082.	0.7	52
56	Initiation of sacubitril/valsartan shortly after hospitalisation for acutely decompensated heart failure in patients with newly diagnosed (de novo) heart failure: a subgroup analysis of the TRANSITION study. <i>European Journal of Heart Failure</i> , 2020, 22, 303-312.	2.9	52
57	Congestive Heart Failure in Elderly Patients. <i>Mayo Clinic Proceedings</i> , 1997, 72, 453-460.	1.4	50
58	Perioperative management of oral antiplatelet therapy and clinical outcomes in coronary stent patients undergoing surgery. <i>Thrombosis and Haemostasis</i> , 2015, 113, 272-282.	1.8	46
59	Exploring New Endpoints for Patients With Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2016, 9, .	1.6	46
60	Prognostic scores in heart failure â€” Critical appraisal and practical use. <i>International Journal of Cardiology</i> , 2015, 188, 1-9.	0.8	45
61	Aspirin Desensitization in Patients With Coronary Artery Disease. <i>Circulation: Cardiovascular Interventions</i> , 2017, 10, .	1.4	43
62	Rationale and design of <scp>TRANSITION</scp>: a randomized trial of preâ€discharge vs. postâ€discharge initiation of sacubitril/valsartan. <i>ESC Heart Failure</i> , 2018, 5, 327-336.	1.4	42
63	Predictive accuracy of CHA2DS2-VASc and HAS-BLED scores in patients without atrial fibrillation undergoing percutaneous coronary intervention and discharged on dual antiplatelet therapy. <i>International Journal of Cardiology</i> , 2015, 199, 319-325.	0.8	39
64	Temporal Trends in Survival and Hospitalizations in Outpatients With Chronic Systolic Heart Failure in 1995 and 1999. <i>Journal of Cardiac Failure</i> , 2005, 11, 270-278.	0.7	38
65	Safety and Tolerability of Neladenoson Bialanate, a Novel Oral Partial Adenosine A1 Receptor Agonist, in Patients With Chronic Heart Failure. <i>Journal of Clinical Pharmacology</i> , 2017, 57, 440-451.	1.0	38
66	Changes in Serum Potassium Levels During Hospitalization in Patients With Worsening Heart Failure and Reduced Ejection Fraction (from the EVEREST Trial). <i>American Journal of Cardiology</i> , 2015, 115, 790-796.	0.7	37
67	Sacubitril/valsartan reduces serum uric acid concentration, an independent predictor of adverse outcomes in PARADIGMâ€HF. <i>European Journal of Heart Failure</i> , 2018, 20, 514-522.	2.9	35
68	Analysis of Circumferential and Longitudinal Left Ventricular Systolic Function in Patients With Non-Ischemic Chronic Heart Failure and Preserved Ejection Fraction (from the CARRY-IN-HFpEF Study). <i>American Journal of Cardiology</i> , 2012, 109, 383-389.	0.7	34
69	Heart rate as a prognostic marker and therapeutic target in acute and chronic heart failure. <i>International Journal of Cardiology</i> , 2018, 253, 97-104.	0.8	34
70	Lessons learned in acute heart failure. <i>European Journal of Heart Failure</i> , 2018, 20, 630-641.	2.9	33
71	Preâ€discharge and early postâ€discharge troponin elevation among patients hospitalized for heart failure with reduced ejection fraction: findings from the ASTRONAUT trial. <i>European Journal of Heart Failure</i> , 2018, 20, 281-291.	2.9	33
72	The 30â€day metric in acute heart failure revisited: data from <scp>INâ€HF</scp> Outcome, an Italian nationwide cardiology registry. <i>European Journal of Heart Failure</i> , 2015, 17, 1032-1041.	2.9	32

#	ARTICLE	IF	CITATIONS
73	Cardiac magnetic resonance in heart failure with preserved ejection fraction: myocyte, interstitium, microvascular, and metabolic abnormalities. <i>European Journal of Heart Failure</i> , 2020, 22, 1065-1075.	2.9	31
74	Rationale and design of a multicentre, randomized, placebo-controlled trial of mirabegron, a Beta3-adrenergic receptor agonist on left ventricular mass and diastolic function in patients with structural heart disease Beta3-left ventricular hypertrophy (Beta3-LVH). <i>ESC Heart Failure</i> , 2018, 5, 830-841.	1.4	29
75	Known and missing left ventricular ejection fraction and survival in patients with heart failure: a MAGGIC meta-analysis report. <i>European Journal of Heart Failure</i> , 2013, 15, 1220-1227.	2.9	28
76	Baroreflex activation therapy for the treatment of heart failure with reduced ejection fraction in patients with and without coronary artery disease. <i>International Journal of Cardiology</i> , 2018, 266, 187-192.	0.8	27
77	Angioedema in heart failure patients treated with sacubitril/valsartan (LCZ696) or enalapril in the PARADIGM-HF study. <i>International Journal of Cardiology</i> , 2018, 264, 118-123.	0.8	27
78	Safety and efficacy of the partial adenosine A1 receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced ejection fraction: a phase IIb, randomized, double-blind, placebo-controlled trial. <i>European Journal of Heart Failure</i> , 2019, 21, 1426-1433.	2.9	27
79	Restrictive mitral valve annuloplasty versus mitral valve replacement for functional ischemic mitral regurgitation: An exercise echocardiographic study. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2014, 148, 447-453.e2.	0.4	26
80	Impact of bridging with perioperative low-molecular-weight heparin on cardiac and bleeding outcomes of stented patients undergoing non-cardiac surgery. <i>Thrombosis and Haemostasis</i> , 2015, 114, 423-431.	1.8	26
81	Surgical Experience and Long-term Results of Baroreflex Activation Therapy for Heart Failure With Reduced Ejection Fraction. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 2016, 28, 320-328.	0.4	26
82	Sacubitril/valsartan therapeutic strategy in HFpEF: Clinical insights and perspectives. <i>International Journal of Cardiology</i> , 2019, 281, 158-165.	0.8	26
83	Impact of clinical and subclinical coronary artery disease as assessed by coronary artery calcium in COVID-19. <i>Atherosclerosis</i> , 2021, 328, 136-143.	0.4	25
84	Baseline characteristics of patients in the Reduction of Events with Darbeopetin alfa in Heart Failure trial (RED-HF). <i>European Journal of Heart Failure</i> , 2013, 15, 334-341.	2.9	24
85	Do Existing Definitions Identify Subgroup Phenotypes or Reflect the Natural History of Heart Failure With Preserved Ejection Fraction?. <i>Circulation</i> , 2019, 140, 366-369.	1.6	24
86	Treatment with inotropes and related prognosis in acute heart failure: Contemporary data from the Italian Network on Heart Failure (IN-HF) Outcome registry. <i>Journal of Heart and Lung Transplantation</i> , 2014, 33, 1056-1065.	0.3	23
87	Surgical ventricular reverse remodeling in severe ischemic dilated cardiomyopathy: The relevance of the left ventricular equator as a prognostic factor. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2006, 131, 357-363.e1.	0.4	21
88	NT-proBNP Response to Sacubitril/Valsartan in Hospitalized Heart Failure Patients With Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , 2020, 8, 822-833.	1.9	21
89	Integrating High-Sensitivity Troponin T and Sacubitril/Valsartan Treatment in AHFpEF. <i>JACC: Heart Failure</i> , 2021, 9, 627-635.	1.9	21
90	Clinical features, and in-hospital and 1-year mortalities of patients with acute heart failure and severe renal dysfunction. Data from the Italian Registry IN-HF Outcome. <i>International Journal of Cardiology</i> , 2013, 168, 3691-3697.	0.8	20

#	ARTICLE	IF	CITATIONS
91	Atrial fibrillation, cognitive impairment, frailty and disability in older heart failure patients. <i>Journal of Cardiovascular Medicine</i> , 2016, 17, 616-623.	0.6	20
92	The risk of coronary artery disease after heart transplantation is increased in patients receiving low-dose cyclosporine, regardless of blood cyclosporine levels. <i>Clinical Cardiology</i> , 1997, 20, 767-772.	0.7	19
93	Prevention of Left Ventricular Remodelling after Acute Myocardial Infarction: An Update. <i>Recent Patents on Cardiovascular Drug Discovery</i> , 2010, 5, 196-207.	1.5	18
94	Bridge therapy or standard treatment for urgent surgery after coronary stent implantation: Analysis of 314 patients. <i>Vascular Pharmacology</i> , 2016, 80, 85-90.	1.0	18
95	Sacubitril/valsartan (LCZ696) for the treatment of heart failure. <i>Expert Review of Cardiovascular Therapy</i> , 2016, 14, 145-153.	0.6	18
96	Grey zones in cardiomyopathies: defining boundaries between genetic and iatrogenic disease. <i>Nature Reviews Cardiology</i> , 2017, 14, 102-112.	6.1	18
97	Aortic valve disease with severe ventricular dysfunction: stentless valve for better recovery. <i>Annals of Thoracic Surgery</i> , 2002, 74, 2016-2021.	0.7	17
98	Bacterial Pericarditis due to <i>Providencia stuartii</i> . <i>Circulation</i> , 2010, 122, e401-3.	1.6	17
99	Addressing the Heterogeneity of Heart Failure in Future Randomized Trials. <i>Current Heart Failure Reports</i> , 2017, 14, 197-202.	1.3	17
100	Safety and Tolerability of the Chymase Inhibitor Fulacimstat in Patients With Left Ventricular Dysfunction After Myocardial Infarction—Results of the CHIARA MIA 1 Trial. <i>Clinical Pharmacology in Drug Development</i> , 2019, 8, 942-951.	0.8	17
101	Heart failure at the crossroads: moving beyond blaming stakeholders to targeting the heart. <i>European Journal of Heart Failure</i> , 2015, 17, 760-763.	2.9	16
102	Determinants of functional capacity after mitral valve annuloplasty or replacement for ischemic mitral regurgitation. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2015, 149, 1595-1603.	0.4	16
103	Monitoring of biomarkers in heart failure. <i>European Heart Journal Supplements</i> , 2019, 21, M5-M8.	0.0	16
104	Usefulness of regional right ventricular and right atrial strain for prediction of early and late right ventricular failure following a left ventricular assist device implant: A machine learning approach. <i>International Journal of Artificial Organs</i> , 2020, 43, 297-314.	0.7	16
105	Novel approaches to the post-myocardial infarction/heart failure neural remodeling. <i>Heart Failure Reviews</i> , 2014, 19, 611-619.	1.7	15
106	Low Incidence of Gastrointestinal Bleeding and Pump Thrombosis in Patients Receiving the INCOR LVAD System in the Long-term Follow-up. <i>International Journal of Artificial Organs</i> , 2015, 38, 542-547.	0.7	14
107	High-Sensitive Cardiac Troponin for Prediction of Clinical Heart Failure. <i>Circulation</i> , 2017, 135, 1506-1508.	1.6	14
108	Angiotensinâ€‘neprilysin inhibition and renal outcomes across the spectrum of ejection fraction in heart failure. <i>European Journal of Heart Failure</i> , 2022, 24, 1591-1598.	2.9	14

#	ARTICLE	IF	CITATIONS
109	Contrasting acute and chronic effects of tolvaptan on serum osmolality in the EVEREST trial. <i>European Journal of Heart Failure</i> , 2016, 18, 185-191.	2.9	13
110	Exercise Hemodynamic and Functional Capacity After Mitral Valve Replacement in Patients With Ischemic Mitral Regurgitation. <i>Circulation: Heart Failure</i> , 2018, 11, e004056.	1.6	13
111	Dose-dependent efficacy of β -blocker in patients with chronic heart failure and atrial fibrillation. <i>International Journal of Cardiology</i> , 2018, 273, 141-146.	0.8	13
112	How patients with heart failure are managed in Italy. <i>European Journal of Heart Failure</i> , 2001, 3, 257-260.	2.9	12
113	N-terminal fraction of pro-B-type natriuretic peptide versus clinical risk scores for prognostic stratification in chronic systolic heart failure. <i>European Journal of Preventive Cardiology</i> , 2018, 25, 889-895.	0.8	12
114	Current gaps in HFpEF trials: Time to reconsider patients' selection and to target phenotypes. <i>Progress in Cardiovascular Diseases</i> , 2021, 67, 89-97.	1.6	12
115	Haemodynamics of Heart Failure With Preserved Ejection Fraction: A Clinical Perspective. <i>Cardiac Failure Review</i> , 2016, 2, 102-105.	1.2	12
116	Successful treatment of subacute constrictive pericarditis with interleukin-1 β receptor antagonist (anakinra). <i>Clinical and Experimental Rheumatology</i> , 2015, 33, 294-5.	0.4	12
117	Drug Development for Heart Failure With Preserved Ejection Fraction: What Pieces Are Missing From the Puzzle?. <i>Canadian Journal of Cardiology</i> , 2017, 33, 768-776.	0.8	11
118	Is mild asymptomatic left ventricular systolic dysfunction always predictive of adverse events in high-risk populations? Insights from the DAVID-Berg study. <i>European Journal of Heart Failure</i> , 2018, 20, 1540-1548.	2.9	11
119	Beneficial effects of adaptive servo-ventilation on natriuretic peptides and diastolic function in acute heart failure patients with preserved ejection fraction and sleep-disordered breathing. <i>Sleep and Breathing</i> , 2019, 23, 287-291.	0.9	11
120	Combination decongestion therapy in hospitalized heart failure: loop diuretics, mineralocorticoid receptor antagonists and vasopressin antagonists. <i>Expert Review of Cardiovascular Therapy</i> , 2015, 13, 799-809.	0.6	10
121	Angiotensin receptor-neprilysin inhibitor (ARNi): Clinical studies on a new class of drugs. <i>International Journal of Cardiology</i> , 2017, 226, 136-140.	0.8	10
122	Sacubitril/valsartan in heart failure with reduced ejection fraction: cost and effectiveness in the Italian context. <i>European Journal of Heart Failure</i> , 2017, 19, 1551-1553.	2.9	10
123	Renin-angiotensin-aldosterone system inhibition in patients affected by heart failure: efficacy, mechanistic effects and practical use of sacubitril/valsartan. Position Paper of the Italian Society of Cardiology. <i>European Journal of Internal Medicine</i> , 2022, 102, 8-16.	1.0	10
124	Left main stem patch plasty and aortic root homograft in Takayasu's disease. <i>Annals of Thoracic Surgery</i> , 2004, 77, 314-317.	0.7	9
125	Cardiac Resynchronization In combination with β blocker treatment in advanced chronic Heart Failure (CARIBE-HF): the results of the CARIBE-HF study. <i>Acta Cardiologica</i> , 2011, 66, 573-580.	0.3	9
126	Transcatheter treatment of chronic mitral regurgitation with the MitraClip system. <i>Journal of Cardiovascular Medicine</i> , 2014, 15, 173-188.	0.6	9

#	ARTICLE	IF	CITATIONS
127	Mineralocorticoid Receptor Antagonist Use in Hospitalized Patients With Heart Failure, Reduced Ejection Fraction, and Diabetes Mellitus (from the EVEREST Trial). <i>American Journal of Cardiology</i> , 2014, 114, 743-750.	0.7	8
128	Transvenous pacing in pediatric patients with bipolar lumenless lead: Ten-year clinical experience. <i>International Journal of Cardiology</i> , 2018, 255, 45-49.	0.8	8
129	Sacubitril/valsartan: from a large clinical trial to clinical practice. <i>Journal of Cardiovascular Medicine</i> , 2018, 19, 473-479.	0.6	8
130	Integrating natriuretic peptides and diastolic dysfunction to predict adverse events in high-risk asymptomatic subjects. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 937-945.	0.8	8
131	Hemodynamic arterial changes in heart failure: a proposed new paradigm of "heart and vessels failure". <i>Minerva Cardiology and Angiology</i> , 2022, 70, .	0.4	8
132	Clinical Outcome Predictions for the VeriCiguaT Global Study in Subjects With Heart Failure With Reduced Ejection Fraction (VICTORIA) Trial. <i>Journal of Cardiac Failure</i> , 2021, 27, 949-956.	0.7	8
133	Multiphase transoesophageal echocardiographic detection of thoracic aortic plaque is a marker for coronary artery disease in women. <i>International Journal of Cardiology</i> , 1997, 61, 269-275.	0.8	7
134	Natriuretic peptides and the Framingham Risk score for screening of asymptomatic left ventricular systolic dysfunction in high-risk patients in primary care. The DAVID-BERG study. <i>International Journal of Cardiology</i> , 2013, 168, 5093-5095.	0.8	7
135	Biomarkers of Heart Failure with Preserved and Reduced Ejection Fraction. <i>Handbook of Experimental Pharmacology</i> , 2016, 243, 79-108.	0.9	7
136	Therapeutic options of Angiotensin Receptor Neprilysin inhibitors (ARNis) in chronic heart failure with reduced ejection fraction: Beyond RAAS and sympathetic nervous system inhibition. <i>International Journal of Cardiology</i> , 2017, 226, 132-135.	0.8	7
137	Implantation of an Elastic Ring at Equator of the Left Ventricle Influences Cardiac Mechanics in Experimental Acute Ventricular Dysfunction. <i>Journal of the American College of Cardiology</i> , 2007, 50, 1791-1798.	1.2	6
138	Toward the development of a fully elastic mitral ring: Preliminary, acute, in vivo evaluation of biomechanical behavior. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2009, 137, 174-179.	0.4	6
139	A multidisciplinary consensus document on follow-up strategies for patients treated with percutaneous coronary intervention. <i>Catheterization and Cardiovascular Interventions</i> , 2015, 85, E129-39.	0.7	6
140	Heart failure with preserved ejection fraction in Asia: the far side of the moon?. <i>European Journal of Heart Failure</i> , 2019, 21, 37-39.	2.9	6
141	Clinical application of personalized medicine: heart failure with preserved left ventricular ejection fraction. <i>European Heart Journal Supplements</i> , 2020, 22, L124-L128.	0.0	6
142	Use of implantable cardioverter defibrillator and cardiac resynchronization therapy. <i>Journal of Cardiovascular Medicine</i> , 2012, 13, 675-683.	0.6	5
143	Incremental prognostic value of echocardiography of left ventricular remodeling and diastolic function in STICH trial. <i>Cardiovascular Ultrasound</i> , 2020, 18, 17.	0.5	5
144	Management of heart failure with preserved ejection fraction: from neurohormonal antagonists to empagliflozin. <i>Heart Failure Reviews</i> , 2022, , .	1.7	5

#	ARTICLE	IF	CITATIONS
145	Ranolazine in Heart Failure With Preserved Left Ventricular Ejection Fraction and Microvascular Dysfunction: Case Report and Literature Review. <i>Journal of Clinical Pharmacology</i> , 2013, 53, 665-669.	1.0	4
146	Cardiogenic shock: How to overcome a clinical dilemma. Unmet needs in Emergency medicine. <i>International Journal of Cardiology</i> , 2015, 186, 19-21.	0.8	4
147	Genetic Variants Are Not Associated with Outcome in Patients with Coronary Artery Disease and Left Ventricular Dysfunction: Results of the Genetic Substudy of the Surgical Treatment for Ischemic Heart Failure (STICH) Trials. <i>Cardiology</i> , 2015, 130, 69-81.	0.6	4
148	Strategy to identify subjects with diabetes mellitus more suitable for selective echocardiographic screening: The DAVID-Berg study. <i>International Journal of Cardiology</i> , 2017, 248, 414-420.	0.8	4
149	Global Longitudinal Strain in master athletes and in hypertensive patients with the same degree of septal thickness. <i>Scandinavian Journal of Medicine and Science in Sports</i> , 2017, 27, 1411-1416.	1.3	4
150	The Titan can help titin: from micro to macro myocardial elasticity. <i>Journal of Cardiovascular Medicine</i> , 2006, 7, 153-158.	0.6	3
151	Reasons why patients suffering from chronic heart failure at very high risk for death survive. <i>International Journal of Cardiology</i> , 2014, 177, 213-218.	0.8	3
152	An Intriguing Case Report of Functional Mitral Regurgitation Treated With MitraClip. <i>Medicine (United States)</i> , 2015, 94, e608.	0.4	3
153	Cavotricuspid Isthmus Ablation and Subcutaneous Monitoring Device Implantation in a 2-Year-Old Baby with 2 SCN5A Mutations, Sinus Node Dysfunction, Atrial Flutter Recurrences, and Drug Induced Long-QT Syndrome: A Tricky Case of Pediatric Overlap Syndrome?. <i>Journal of Cardiovascular Electrophysiology</i> , 2015, 26, 346-349.	0.8	3
154	Echocardiographic Outflow Pump Ramp Test in Centrifugal-Flow Left Ventricular Assist Device. <i>International Journal of Artificial Organs</i> , 2017, 40, 128-131.	0.7	3
155	Treating Patients Following Hospitalisation for Acute Decompensated Heart Failure: An Insight into Reducing Early Rehospitalisations. <i>Cardiac Failure Review</i> , 2019, 5, 78-82.	1.2	3
156	Risk stratifying asymptomatic left ventricular systolic dysfunction in the community: beyond left ventricular ejection fraction. <i>European Heart Journal Cardiovascular Imaging</i> , 2020, 21, 1405-1411.	0.5	3
157	Renin profiling predicts neurohormonal response to sacubitril/valsartan. <i>ESC Heart Failure</i> , 2021, 8, 719-724.	1.4	3
158	Medical treatment of end-stage heart failure. <i>Cardiovascular Drugs and Therapy</i> , 1996, 10, 617-622.	1.3	2
159	Reasons why patients suffering from chronic heart failure at very low risk for mortality die. <i>International Journal of Cardiology</i> , 2016, 223, 947-952.	0.8	2
160	A 57-year-old man with rapidly progressive pulmonary hypertension. <i>Monaldi Archives for Chest Disease</i> , 2021, , .	0.3	2
161	Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure with Preserved Ejection Fraction: Rationale for and Practical Use of a Successful Therapy. <i>Cardiac Failure Review</i> , 0, 8, .	1.2	2
162	The Pilot European Survey of Atrial Fibrillation: how to look at heart failure through a keyhole. <i>European Journal of Heart Failure</i> , 2015, 17, 541-543.	2.9	1

#	ARTICLE	IF	CITATIONS
163	Comparison of the Baseline Demographics of the LCZ696 PARADIGM-HF and TITRATION Studies. <i>Journal of Cardiac Failure</i> , 2015, 21, S45.	0.7	1
164	External closed-circuit cooling system for management of patients after device implantation: A feasibility study. <i>International Journal of Cardiology</i> , 2017, 241, 235-237.	0.8	1
165	Prolonged QRS associated with left bundle branch conduction defect is a prognostic red flag in asymptomatic patients at risk for heart failure (ACCF/AHA stages A and B): Insights from the DAVID-Berg study. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 2326-2329.	0.8	1
166	Rationale for and Practical Use of Sacubitril/Valsartan in the Patient's Journey with Heart Failure and Reduced Ejection Fraction. <i>Cardiac Failure Review</i> , 2021, 7, e06.	1.2	1
167	Four aces of heart failure therapy: systematic review of established and emerging therapies for heart failure with reduced ejection fraction. <i>Cardiology Plus</i> , 2022, 7, 20-28.	0.2	1
168	Is 3D Echo With Ramp Test Indicated in Detecting Blood Flow Obstructions in HeartWare LVAD?. <i>Journal of the American College of Cardiology</i> , 2016, 68, 2126-2127.	1.2	0
169	Clinical correlates of autonomic response during tilting test in hypertrophic cardiomyopathy. <i>Journal of Cardiovascular Medicine</i> , 2017, 18, 255-261.	0.6	0
170	Prognostic scores: one fits all?. <i>European Journal of Heart Failure</i> , 2017, 19, 588-588.	2.9	0
171	How should I treat a challenging case of MitraClip implantation?. <i>EuroIntervention</i> , 2014, 10, 887-890.	1.4	0